Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments
Provided By GlobeNewswire
Last update: Feb 18, 2025
Stoke retains exclusive rights for zorevunersen in the United States, Canada, and Mexico; Biogen receives exclusive rest of world commercialization rights
Collaboration broadens Biogen’s rare disease pipeline and leverages global expertise commercializing high-value, disease-modifying medicines for rare genetic diseases
Read more at globenewswire.com140.64
+3.56 (+2.6%)
Find more stocks in the Stock Screener
BIIB Latest News and Analysis
11 days ago - ChartmillTop S&P500 movers in Wednesday's sessionStay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Wednesday.
11 days ago - ChartmillThese S&P500 stocks have an unusual volume in today's sessionLet's take a closer look at the S&P500 stocks with an unusual volume in today's session on Wednesday. Stay informed about the market activity below.
11 days ago - ChartmillThese S&P500 stocks are moving in today's sessionStay informed about the performance of the S&P500 index in the middle of the day on Wednesday. Uncover the top gainers and losers in today's session for valuable insights.
11 days ago - ChartmillWednesday's session: gap up and gap down stock in the S&P500 indexLet's have a look at what is happening on the US markets on Wednesday. Below you can find the S&P500 gap up and gap down stocks in today's session.
